Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

Objective: Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies. However, the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells, thus making some patients inel...

Full description

Bibliographic Details
Main Authors: Lu Han, Jian Zhou, Linlin Li, Keshu Zhou, Lingdi Zhao, Xinghu Zhu, Qingsong Yin, Yufu Li, Hongqin You, Jishuai Zhang, Yongping Song, Quanli Gao
Format: Article
Language:English
Published: China Anti-Cancer Association 2021-11-01
Series:Cancer Biology & Medicine
Subjects:
fewer initial lymphocytes
peripheral blood
car-t cells
b-cell malignancy
acute lymphoblastic leukemia
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1890

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1890

Similar Items